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Treatment of orthopedic infections usually requires prolonged antimicrobial therapy, ran-
ging from 14 days up to 6 months. Nowadays, rising levels of antimicrobial resistance
demands parenteral therapy for many patients. Outpatient parenteral antimicrobial ther-
apy  (OPAT) is a modality that allows treatment out of hospital in these situations. In Brazil,
where a public universal healthcare system allows full coverage for all citizens, implantation
and dissemination of OPAT programs would be beneﬁcial for patients and for the system,
because it would allow a better allocation of health resources. The Instituto de Ortopedia e
Traumatologia do Hospital das Clínicas da Faculdade de Medicina da USP (IOT) started, in July
2013, a partnership with municipal health authorities in Sao Paulo, Brazil, in order to initiate
an  OPAT program in which patients discharged from that hospital would be able to continue
antimicrobial therapy at primary care facilities. When necessary, patients could also receive
their therapy at the day-hospital located at IOT. Primary care nursing and physician staff
were trained about antimicrobial infusion and peripherally inserted central catheter manip-
ulation. An OPAT speciﬁc antimicrobial protocol was designed and a special reference and
counter-reference organized. As a result, 450 primary healthcare professionals were trained.
In  the ﬁrst year of this program, 116 patients were discharged for OPAT. Chronic and acute
osteomyelitis were most frequent diagnosis. Teicoplanin, ertapenem and tigecycline were
the  most used drugs. Duration of treatment varied from 10 to 180 days (average 101, median
42). Total sum of days in OPAT regimen was 11,698. Only 3 patients presented adverse effects.
Partnership between services of different levels of complexity allowed implantation of a safe
and effective public healthcare OPAT program for treatment of orthopedic infections. Thisprogram can serve as a mo
Latin  America.
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ntroduction
ue to special features related to blood supply and local
mmunological mechanisms related to defense against infec-
ion, treatment of orthopedic infections (including bone, joint,
nd soft tissue infections) usually requires prolonged antimi-
robial therapy, ranging from 14 days up to six months in
ases of arthroplasty-related chronic osteomyelitis.1–4 In this
etting of long-lasting therapy, rising levels of antimicro-
ial resistance demands full parenteral therapy for many
atients. Outpatient parenteral antimicrobial therapy (OPAT)
s a modality that allows for treating these cases outside the
ospital. OPAT has been widely used in some countries, with
onsolidated programs and speciﬁc guidelines to help OPAT
ervices to provide quality patient care and to minimize clini-
al risk.5–7 In Latin America, however, no OPAT programs were
mplanted and described until now.
In Brazil, a public universal healthcare system provides
ull coverage for all citizens. In this model of healthcare,
t is believed that implantation and dissemination of OPAT
rograms would be beneﬁcial for the patients and for the sys-
em. It would allow for better allocation of hospital resources
nd offer a highly clinically efﬁcacious, cost-effective, and
afe alternative to inpatient care where parenteral therapy is
eemed necessary. Brazilian healthcare organization provides
anking of services into primary, secondary, and tertiary levels
ccording to the degree of complexity. Generally, tertiary and
econdary-care facilities are under federal or state adminis-
ration. Primary care facilities, otherwise, are under municipal
egulation. Reference and counter-reference protocols should
ntegrate the different levels of healthcare services.8 Establish-
ng an OPAT program in this healthcare system would require
hese protocols to be implemented and published, in order to
ssure safety and efﬁcacy for outpatient therapy.
bjective
o describe the implementation process and the preliminary
esults of a public healthcare OPAT program for treating ortho-
edic infections in Sao Paulo, Brazil.
ethods
he Instituto de Ortopedia e Traumatologia do Hospital das Clíni-
as da Faculdade de Medicina da USP (IOT) is a tertiary hospital
inked to the University of São Paulo and dedicated to care for
igh-complexity orthopedic patients in São Paulo, Brazil. In
uly 2013, this hospital started a partnership with local munic-
pal health authorities in order to initiate an OPAT program in
hich patients discharged from that hospital would be able
o continue antimicrobial therapy at primary care facilities
ocated near their homes. When this was not possible, patients
ould also receive therapy at the day-hospital located at IOT.
Before starting this OPAT program, primary care nurses
taff were trained by IOT professionals about antimicrobial
nfusion techniques and manipulation of central lines. Periph-
rally inserted central catheter (PICC) was considered as the
rst choice of central line in this protocol, Hickman lines6;2 0(3):272–275 273
(HL) were used when PICC insertion was not possible. Hands-
on workshops were designed especially for manipulation of
both devices, in order to familiarize the professionals with
them. Dressing changes were performed once a week for
PICC and HL. PICC lines were ﬂushed with 10 mL saline solu-
tion immediately before and after antimicrobial infusion. HL
were also ﬂushed with 3 mL  of heparin solution (300 UI/mL)
after infusion, and this solution was aspirated before the next
antimicrobial infusion. Primary care physicians were trained,
also by IOT staff, on clinical monitoring of patients during
OPAT.
An OPAT speciﬁc antimicrobial protocol was designed in
order to prioritize infusions qd or bid during the day and with
speciﬁc instructions when necessary (Table 1). Also, a special
reference and counter-reference pathway was organized spe-
cially to this program, in order to assure rapid referral to IOT  in
case of adverse events related to antimicrobial infusion. This
pathway also included previous communication to primary-
care or day-hospital staff before patient discharge to OPAT, as
well as a written detailed planning about patient care outside
the hospital. Patients and their caregivers received informa-
tion about adequate CL care and the importance of adhering
to the protocol.9
The main inclusion criterion for this protocol was indi-
cation for prolonged parenteral antimicrobial therapy, based
on results of culture and antimicrobial susceptibility tests.
In addition, patients were to be clinically stable, regarding
both the infectious condition and possible associated comor-
bidities. Exclusion criteria were inability to understand the
risks of intravenous therapy and appropriate care of CL, as
well as the lack of adequate transport to where antimicro-
bials would be infused (primary care facility or day-hospital).
Patients with history of active drug addiction or alcoholism
were also excluded from the protocol because of the risk of
improper manipulation of the CL.
In November 2013, after these initial steps, this OPAT pro-
gram was started.
Results
As a result of this partnership, 450 primary healthcare profes-
sionals were trained, including nurses and physicians. In the
ﬁrst year of this program, until November 2014, 116 patients
were discharged for continuing antimicrobial therapy in out-
patient setting. There was a predominance of male patients
(72%) and the average age of the group was 39.3 years (varia-
tion from 8 to 76 years, median 38 years). A total of 82 patients
(70%) received therapy at primary care facilities and 34 (30%) at
the day-hospital located at IOT. The vast majority of the group
involved in this protocol, 114 patients (98.3%), used PICC lines
for antimicrobial infusion, only two patients (1.72%) used HL.
Chronic and acute osteomyelitis were the most frequent
diagnosis, 51 patients (43.96%) of each diagnosis. Table 2 shows
the patient distribution according to diagnosis; 98 patients
(84.5%) received only one antimicrobial and 18 patients (15.5%)
were treated with a combination of two antimicrobials. One
patient, with spinal tuberculosis and intolerance to ethamb-
utol needed therapy with streptomycin, a drug that was not
initially included in OPAT protocol. It was necessary to include
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Table 1 – Speciﬁc antimicrobial protocol for outpatient parenteral antimicrobial therapy.
Antimicrobial Dosage regimen
for normal renal
function
Possible colateral effects Monitoring Special observations
Teicoplanin 400–600 mg qd - Skin rash
- Renal impairment
- Liver impairment
- Bone marrow impairment
(mainly leucopenia)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
Ertapenem 1 g qd - Liver impairment
- Convulsions
- Mental confusion (specially
in elderly)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
Ceftriaxone 2 g qd - Liver impairment
- Bone marrow impairment
(mainly leucopenia)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
Vancomycin 1 g q12 hours - Skin rash
- Renal impairment
- Liver impairment
- Bone marrow impairment
(mainly leucopenia)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a week
-  Contact hospital (IOT)
team if abnormalities
- Slow infusion
Meropenem 2 g q12 hours - Liver impairment
- Convulsions
- Mental confusion (specially
in elderly)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
Ceftazidime 2 g q12 hours - Liver impairment
- Bone marrow impairment
(mainly leucopenia)
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
Tigecycline 50 mg q12 hours - Liver impairment
- Cholestasis
- Nausea/vomiting
Urea,  creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a month
-  Contact hospital (IOT)
team if abnormalities
- Nausea may demand
antiemetic infusion before
antibiotic
Linezolid 600 mg q12 hours - Bone marrow impairment
(mainly anemia)
- Optic nerve impairment
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram once a week
-  Contact hospital (IOT)
team if abnormalities
Colistin 150 mg q12 hours - Renal impairment
- Peripheral neuropathy
Urea,  creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram twice a week
-  Contact hospital (IOT)
team if abnormalities
Amicacin 1 g qd - Renal impairment
- Hearing impairment
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram twice a week
-  Contact hospital (IOT)
team if abnormalities
Gentamycin 240 mg qd - Renal impairment
- Hearing impairment
Urea, creatinine, AST, ALT, alkaline
phosphatase, gamma GT and
hemogram twice a week
-  Contact hospital (IOT)
team if abnormalities
Table 2 – Distribution of patients on outpatient
parenteral antimicrobial therapy according to diagnosis.
Diagnosis Number of patients %
Soft tissue infection 13 11.20
Chronic osteomyelitis 51 43.96
Table 3 – Antimicrobials used for treating orthopedic
infections in outpatient parenteral antimicrobial therapy.
Antimicrobial Number of patients %
Teicoplanin 53 39.55
Ertapenem 22 16.42
Tigecycline 13 9.70
Vancomycin 12 8.96
Meropenem 10 7.46
Ceftazidime 9 6.72
Linezolid 5 3.73
Ceftriaxone 3 2.24
Colistin 3 2.24Acute osteomyelitis 51 43.96
Spinal tuberculosis 1 0.86
intravenous linezolid in this protocol because of the ﬁnancial
difﬁculties to access the oral presentation of this drug at public
healthcare setting in Brazil.
Teicoplanin (40%), ertapenem (16%), and tigecycline (10%)
were the most frequently used antimicrobials, as shown in
Table 3. The duration of treatment varied from 10 to 180 days
(average 101 days, median 42 days). The total sum of days in
OPAT regimen was 11,698.
Amycacin 2 1.49
Streptomycin 1 0.75
Gentamycin 1 0.75
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outpatient parenteral antibiotic therapy team: challenges and
solutions. Ther Clin Risk Manag. 2014;10:459–65,
http://dx.doi.org/10.2147/TCRM.S48906.b r a z j i n f e c t d i s .
Only three patients presented adverse effects during OPAT
nd required readmission to the hospital. Two patients had
igns of infection related to PICC line insertion, without blood
tream dissemination, and one patient had liver impairment
nd cholestasis during therapy. All of them had favorable out-
omes after speciﬁc measures.
iscussion
PAT has already demonstrated its suitability, as it leads
o faster return home to daily activities and less risk of
cquiring healthcare-related infections and other severe
omplications.10,11 Beyond these direct beneﬁts for the
atients eligible for this modality of antimicrobial treat-
ent, OPAT also can indirectly beneﬁt the healthcare system
y allowing better allocation of ﬁnancial resources and in-
ospital bed availability. This is of particular importance in
ountries with universal public healthcare coverage, such as
razil. Our OPAT protocol for orthopedic infections, including
hose related to soft tissue or bone and joint, made possible, in
ne year alone, 11,698 bed-days at the orthopedics ward to be
edirected to patients really needing to be hospitalized, such
s trauma victims or those requiring elective surgeries.
Only three patients presented adverse effects during this
PAT program, all of them rapidly diagnosed and solved. This
nding demonstrates that training of primary care profes-
ionals for massive use of PICC lines as infusion devices was
ffective, as well as the reference and counter reference pro-
ocol developed.
This study has some limitations, since it did not assess
atients’ satisfaction and quality of life of those on OPAT. In
ddition, no cost-effectiveness analysis of OPAT was under-
aken. Therefore, more  comprehensive studies evaluating
PAT in Brazilian and Latin American settings are warranted.
onclusion
he partnership between medical services of different lev-
ls of complexity allowed for the establishment of a safe and
ffective OPAT program for treating orthopedic infections in
ublic health centers of São Paulo, Brazil. This program can
erve as a model for developing similar strategies in other
egions of Brazil and Latin America.onﬂicts  of  interest
he authors declare no conﬂicts of interest.6;2 0(3):272–275 275
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